Your browser doesn't support javascript.
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
Lapointe, Hope R; Mwimanzi, Francis; Cheung, Peter K; Sang, Yurou; Yaseen, Fatima; Kalikawe, Rebecca; Datwani, Sneha; Waterworth, Rachel; Umviligihozo, Gisele; Ennis, Siobhan; Young, Landon; Dong, Winnie; Kirkby, Don; Burns, Laura; Leung, Victor; Holmes, Daniel T; DeMarco, Mari L; Simons, Janet; Matic, Nancy; Montaner, Julio S G; Brumme, Chanson J; Prystajecky, Natalie; Niikura, Masahiro; Lowe, Christopher F; Romney, Marc G; Brockman, Mark A; Brumme, Zabrina L.
  • Lapointe HR; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
  • Mwimanzi F; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Cheung PK; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
  • Sang Y; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Yaseen F; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Kalikawe R; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
  • Datwani S; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Waterworth R; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Umviligihozo G; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Ennis S; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Young L; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Dong W; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, BC, Canada.
  • Kirkby D; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
  • Burns L; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
  • Leung V; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Holmes DT; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, BC, Canada.
  • DeMarco ML; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Simons J; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Matic N; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Montaner JSG; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Brumme CJ; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Prystajecky N; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Niikura M; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Lowe CF; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Romney MG; Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, BC, Canada.
  • Brockman MA; Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC, Canada.
  • Brumme ZL; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Front Immunol ; 13: 947021, 2022.
Article in English | MEDLINE | ID: covidwho-2316385
ABSTRACT
SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or have recovered from prior variant infection, but few reports have immunologically assessed serial Omicron infections. We characterized SARS-CoV-2 humoral responses in an individual who acquired laboratory-confirmed Omicron BA.1.15 ten weeks after a third dose of BNT162b2, and BA.2 thirteen weeks later. Responses were compared to 124 COVID-19-naive vaccinees. One month post-second and -third vaccine doses, the participant's wild-type and BA.1-specific IgG, ACE2-displacement and virus neutralization activities were average for a COVID-19-naive triple-vaccinated individual. BA.1 infection boosted the participant's responses to the cohort ≥95th percentile, but even this strong "hybrid" immunity failed to protect against BA.2. Reinfection increased BA.1 and BA.2-specific responses only modestly. Though vaccines clearly protect against severe disease, results highlight the continued importance of maintaining additional protective measures to counteract the immune-evasive Omicron variant, particularly as vaccine-induced immune responses naturally decline over time.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.947021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.947021